Earnings Call Summary | Allogene Therapeutics(ALLO.US) Q1 2024 Earnings Conference
Earnings Call Summary | Allogene Therapeutics(ALLO.US) Q1 2024 Earnings Conference
The following is a summary of the Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript:
以下是Allogene Therapeutics, Inc.（ALLO）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Allogene Therapeutics reported a Q1 2024 cash balance of $397.3 million.
The company's Q1 2024 research and development expenses were $52.3 million, contributing to a net loss of $65 million or $0.38 per share.
An additional $110 million equity financing will enhance their cash balance to about $500 million.
For 2024, the company projects a cash burn of approximately $200 million with an estimated full-year GAAP operating expense of about $300 million.
Allogene Therapeutics报告称，2024年第一季度现金余额为3.973亿美元。
该公司2024年第一季度的研发费用为5,230万美元，净亏损6500万美元，合每股亏损0.38美元。
额外的1.1亿美元股权融资将使他们的现金余额增加到约5亿美元。
该公司预计2024年的现金消耗约为2亿美元，预计全年GAAP运营支出约为3亿美元。
Business Progress:
业务进展：
Allogene Therapeutics is advancing major programs, including the ALPHA3 trial for B cell lymphoma with potential revenue growth from $500 million to over $6 billion.
The company has increased its territory rights to include the European Union and the U.K., raising the potential future revenue for its product, cema-cel, by over 50%.
Allogene is exploring the autoimmune space with ALLO-329 and was awarded a $15 million grant for the advancement of their ALLO-316 program for solid tumors.
The company is in the process of expanding the Phase 1 and Phase 2 cohorts of its ALPHA3 program while making strategic preparations for its cema-cel clinical trials in Europe.
An anticipated boost in investment will be committed to cloud infrastructure for the expansion of cema-cel.
Expected proof of concept for ALLO-329 is anticipated by the end of 2025 with IND planned for Q1 2025.
Allogene Therapeutics正在推进重大项目，包括针对B细胞淋巴瘤的 ALPHA3 试验，其收入可能从5亿美元增长到60亿美元以上。
该公司增加了其领土权，将欧盟和英国包括在内，将其产品cema-cel的潜在未来收入提高了50％以上。
Allogene正在利用 ALLO-329 探索自身免疫领域，并获得了1500万美元的拨款，用于推进其针对实体瘤的 ALLO-316 计划。
该公司正在扩大其 ALPHA3 计划的第一阶段和第二阶段队列，同时为其在欧洲的cema-cel临床试验做战略准备。
预计投资将增加用于扩展cema-cel的云基础设施。
ALLO-329 的概念验证预计将于 2025 年底完成，IND 计划于 2025 年第一季度进行。
More details: Allogene Therapeutics IR
更多详情： 异基因疗法 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。